CD20+CD3+ cells, irrespective of their isolation from WM of HD, NAWM, and WM lesions of MS patients, showed a high expression of markers for tissue homing (CXCR6), proliferation (Ki-67), and cytotoxicity (granzyme B) when compared to CD20-CD8+ TRM cells, regardless of CD103 expression [31]. The gene discussed is MS4A1; the disease is myeloid sarcoma.